Editorial on the relationship between suPAR and CKD, published in NEJM

Wed Oct 21 2020

“A suPAR Biomarker for Chronic Kidney Disease”, published in the New England Journal of Medicine

The worldwide epidemic of Chronic Kidney Disease constitutes a death sentence in regions of the world where renal-replacement therapies are not available. Since decreased renal function is only detected after substantial kidney injury has already occurred, there is an urgent need to identify new biomarkers that accurately determine the risk of impending chronic kidney disease while renal function is still well preserved and there is higher likelihood that medical interventions can slow or prevent progression.

Studies that show that intervention based on suPAR levels is beneficial could cement a relationship between suPAR and chronic kidney disease.

Read the editorial here.

900+

published suPAR studies in leading medical journals

Nature Medicine Logo
Science Journal Logo
JAMA Pediatrics Logo

The suPARnostic® brand consists of 3 products:

Quick Triage

A Point of Care Solution

TurbiLatex

For Automated Systems

ELISA Assay

Clinical and Research

suPAR is used in clinical routine in 48 hospitals

48 hospitals use suPAR in clinical routine for triage of patients in the Emergency Departments and COVID-19 units. Clinical routine is defined by the placement of two Purchasing Orders within the last 12 months rolling.
This period covers January 1, 2022, until December 31, 2022. Some hospital locations cannot be disclosed due to confidentiality.

New Webinar

Webinar

Catch COVID-19

-Improve your triage

Sign up to view webinar recording

View recording

suPARnostic® by ViroGates